Tag: Astellas Pharma

Cell and Gene Therapy, Industry

BioMarin says gene therapy hold will endure as FDA questions cancer risk

February 18, 2022

Via: Biopharma Dive

With more and more gene therapies advancing into clinical testing, the FDA has paid close attention to signs of safety risks, issuing orders to stop testing in a number of recent cases involving developers like UniQure, Bluebird bio, Pfizer and […]